Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
Public ClinicalTrials.gov record NCT01366131. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease
Study identification
- NCT ID
- NCT01366131
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- MEGF0444A Drug
- bevacizumab Drug
- carboplatin Drug
- paclitaxel Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2011
- Primary completion
- Jan 31, 2013
- Completion
- Not listed
- Last update posted
- Nov 1, 2016
Started 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35205 | — |
| Not listed | Hot Springs | Arkansas | 71913 | — |
| Not listed | Santa Monica | California | 90404 | — |
| Not listed | Orlando | Florida | 32904 | — |
| Not listed | Port Saint Lucie | Florida | 34952 | — |
| Not listed | St. Petersburg | Florida | 33719 | — |
| Not listed | Tampa | Florida | 33603 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Indianapolis | Indiana | 46260 | — |
| Not listed | Wichita | Kansas | 67214-3728 | — |
| Not listed | Burnsville | Minnesota | 55337 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | Columbus | Ohio | 43219 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Hershey | Pennsylvania | 17033 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Austin | Texas | 78731 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01366131, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01366131 live on ClinicalTrials.gov.